Get the Stockscreener App
0.4498
1.40%
-0.0064
Pavmed Inc stock is traded at $0.4498, with a volume of 116.16K.
It is down -1.40% in the last 24 hours and down -21.50% over the past month.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
See More
Previous Close:
$0.4562
Open:
$0.45
24h Volume:
116.16K
Relative Volume:
0.58
Market Cap:
$7.69M
Revenue:
$4.03M
Net Income/Loss:
$24.32M
P/E Ratio:
-0.1046
EPS:
-4.3008
Net Cash Flow:
$-45.76M
1W Performance:
-1.55%
1M Performance:
-21.50%
6M Performance:
-43.06%
1Y Performance:
-35.83%
1-Day Range:
$0.43
$0.4699
1-Week Range:
$0.43
$0.48
52-Week Range:
$0.304
$1.90
Pavmed Inc Stock (PAVM) Company Profile
Name
Pavmed Inc
Sector
Industry
Phone
(212) 949-4319
Address
360 MADISON AVENUE, NEW YORK, NY
Compare PAVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
0.4498 | 7.89M | 4.03M | 24.32M | -45.76M | -4.3008 |
|
ABT
Abbott Laboratories
|
131.75 | 225.01B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.17 | 154.32B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
381.91 | 144.71B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
93.02 | 117.85B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.26 | 45.90B | 5.69B | 1.41B | 577.90M | 6.95 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-05-20 | Initiated | Ascendiant Capital Markets | Buy |
| Jun-28-18 | Initiated | Maxim Group | Buy |
Pavmed Inc Stock (PAVM) Latest News
PAVmed Reports Q2 2025 Financial Results and Developments - MSN
PAVmed reports Q2 non-GAAP EPS (5c) vs. (84c) last year - MSN
PAVmed Reports Q2 2025 Financial Results: $13.3M Net Loss, $1.2M in Lucid Diagnostics Revenue - AInvest
PAVmed Q2 2025 slides reveal dramatic cost reduction amid Lucid Diagnostics growth By Investing.com - Investing.com South Africa
PAVmed Inc (PAVM) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... By GuruFocus - Investing.com Canada
PAVmed 2025 Q2 Earnings Net Loss Narrows by 17.4% - AInvest
Lucid Diagnostics Advances Towards Medicare Coverage - MSN
PAVmed Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
PAVmed's EsoGuard Cancer Test Hits 2,756 Q2 Tests as Medicare Coverage Decision Nears - Stock Titan
PAVmed Inc. SEC 10-Q Report - TradingView
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results - BioSpace
Lucid Diagnostics Reports Q2 2025 Financial Results - TipRanks
PAVmed's Q2 2025 Earnings Call: Unraveling Contradictions in Medicare Strategy, FDA Timelines, and Biopharma Expansion - AInvest
Transcript : PAVmed Inc., Lucid Diagnostics Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
Earnings call transcript: Lucid Diagnostics highlights Q2 2025 growth and Medicare focus - Investing.com India
Lucid Diagnostics Inc: Navigating Earnings Challenges and Strategic Growth in a Competitive Diagnostics Landscape - AInvest
What makes PAVmed Inc. stock price move sharplyShort-Term Explosive Growth - thegnnews.com
PAVmed's Q2 2025 Earnings: A Strategic Inflection Point in Healthcare Innovation and Financial Turnaround - AInvest
PAVmed PAVM 2025Q2 Earnings Preview Upside Potential Driven by Strategic Innovations - AInvest
Lucid Diagnostics to Participate in Upcoming Investor Conferences - Eastern Progress
Published on: 2025-08-05 15:46:56 - metal.it
Cancer Prevention Leader Lucid Diagnostics Headlines Two Major Healthcare Investment Conferences This Month - Stock Titan
Trendline Breach Raises Concern for PAVmed Inc. InvestorsTriple Return Setup With Risk Control Explained - metal.it
PAVmed Inc. Forms Bullish Flag — Upside AheadEntry Plan for Oversold Reversal Stocks Released - metal.it
PAVmed Inc. Crosses 200 Day MA — Signal or NoiseReal-Time Analysis With Entry Targets In Progress - metal.it
Is PAVmed Inc. a growth stock or a value stockHigh-velocity gains - Jammu Links News
What are analysts’ price targets for PAVmed Inc. in the next 12 monthsUnlock exclusive stock analysis for investors - Jammu Links News
What analysts say about PAVmed Inc. stockUnlock powerful trading alerts for success - Jammu Links News
What are the latest earnings results for PAVmed Inc.Free Stock Selection - Jammu Links News
Does PAVmed Inc. stock perform well during market downturnsTrack high-yield stocks before they peak - Jammu Links News
When is PAVmed Inc. stock expected to show significant growthTremendous portfolio expansion - Jammu Links News
How strong is PAVmed Inc. company’s balance sheetCapitalize on emerging market sectors - Jammu Links News
What markets is BHST expanding into Is PAVmed Inc. stock a good long term investment option - Jammu Links News
PAVmed to Host Business Update Conference Call on August 14, 2025 - AInvest
Nasdaq Grants PAVmed 180-Day Extension to Meet Minimum Bid Price Rule - AInvest
Pavmed Inc. shares fall 1.22% after-hours following announcement of a business update conference call. - AInvest
PAVmed gets 180-day extension to regain Nasdaq listing compliance - MSN
PAVmed to Host Business Update Conference Call on August 14, 2025. - AInvest
PAVmed CEO and CFO to Present Q2 2025 Results and Growth Strategy Update on August 14 - Stock Titan
Pattern recognition hints at PAVmed Inc. upsideCommunity Shared Smart Money Signals Show Movement - metal.it
Should I hold or sell PAVmed Inc. stock in 2025Advanced Screener Ideas For Fast Growth - Jammu Links News
Lucid Diagnostics to Host Business Update Conference Call and Webcast on August 13, 2025 - AInvest
PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule - 富途牛牛
Why PAVmed Inc. stock attracts strong analyst attentionGrowth Based Investment Plan Guidance Highlighted - beatles.ru
Pavmed Inc Stock (PAVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.74%
0.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):